Systemic coagulation activation and thrombotic complications are frequent among critically ill patients with COVID-19. Limited data are available in non-intensive care unit (ICU) patients.
To determine the incidence, risk factors and prognosis of venous thromboembolism (VTE) in non-ICU COVID-19 patients.
We studied consecutive COVID-19 patients admitted to general ward at Strasbourg Hospital, France (25.02.2020–19.04.2020). The primary outcome was any VTE complication. The secondary outcome was the composite of death or transfer to ICU.
Among the 289 patients included (62.2±17.0 years, 59.2% male), VTE occurred in 49 (17.0%). Padua prediction score for VTE was similar between VTE and non-VTE patients. VTE imaging tests were performed in 100 (34.6%) patients and VTE diagnosed in median 7 (3–11) days after admission. On-admission, time from symptom onset to admission (OR 1.07, CI 95% [1.00–1.16], P=0.045), Improve score (OR 1.37, [1.02–1.83], P=0.032), leukocyte count (OR 1.16, [1.06–1.27], P=0.001) and lack of thromboprophylaxis (OR 27.85, CI 95% [9.35–82.95], P<0.001) were independent predictors of VTE. The incidence of the composite of death or ICU transfer was 31.0% and more frequent among patients with VTE (47.9% vs. 27.9%, P=0.01). Fever (OR 5.37, CI 95% [1.44–19.97], P=0.012), VTE (OR 3.44, CI 95% [1.63–7.25], P=0.001), lymphopenia (OR 0.32, 95% CI [0.15–0.71]; P=0.005) and extent of COVID-19 evaluated by chest CT severity (OR 1.56, 95% CI [1.12–2.16]; P=0.007) were independently associated with in-hospital death or transfer to ICU (Table 1, Fig. 1).
The 17.0% incidence of VTE in non-ICU patients with COVID-19 was associated with worse outcomes. Given the high incidence of VTE in ward patients, there is an urgent need to investigate the optimal anticoagulation regimen.
Le texte complet de cet article est disponible en PDF.
Publié par Elsevier Masson SAS.